NRAS and hepatocellular carcinoma: To confirm whether liver-specific Prmt5 deficiency could achieve remission of autochthonous HCC, Akt/N-Ras-based HTVi and tamoxifen-inducible deletion of Prmt5 specifically within the liver were used in Prmt5flox/flox-Alb-CreERT2 mice (Figure 6B).